ABSTRACT

Biosimilar is a biological product almost similar to an existing approved product obtained from natural sources and having a complex structure. Biosimilars differ in development, evaluation and regulatory approval from the reference product. Biosimilars are being utilized in the treatment of various diseases like inflammatory bowel diseases (IBD), rheumatoid arthritis, renal conditions, oncologic conditions, etc. And its use in various other diseases is under research and progress. Keywords: Biosimilar, IBD, Rheumatoid arthritis, oncologic, reference product
Publication date: 01/03/2022

https://ijbpas.com/pdf/2022/March/MS_IJBPAS_2022_5945.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2022/11.3.5945